Valcyte Heritage

Valcyte—prescribed for over a decade in the prevention of cytomegalovirus (CMV)
disease in high-risk (D+/R-)* adult and pediatric transplant patients

Valcyte Milestones

2003

2009

2010

2015

Tablets approved for the prevention of CMV disease in adult kidney, heart, or kidney-pancreas transplant patients at high risk (D+/R-)1,2

Tablets and Oral Solution approved for the prevention of CMV disease in pediatric kidney or heart transplant patients at high risk (4 months to 16 years)2

Recommended dosing of tablets extended to 200 days post-transplant for the prevention of CMV disease in adult kidney transplant patients at high risk2

12th Anniversary since launch in 20032

About Valcyte

Valcyte® (valganciclovir hydrochloride) is a cytomegalovirus (CMV) nucleoside analogue DNA polymerase inhibitor indicated in adult patients for the prevention of CMV disease in kidney, heart, or kidney-pancreas transplant patients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R−]), and for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS).1

Valcyte is indicated in pediatric patients for the prevention of CMV disease in kidney or heart transplant patients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R−]).1

For each of these Valcyte patient populations, learn about: